Working_Class
Bluelighter
- Joined
- Aug 12, 2019
- Messages
- 523
I've seen this on a vendor recently and am wondering what the difference might be pharmacologically. Any ideas?
-
OD Moderators: Keif’ Richards | negrogesic
Benzos Ethylbromazolam
- Thread starter Working_Class
- Start date
4DQSAR
Bluelighter
- Joined
- Feb 3, 2025
- Messages
- 899
I cannot even find the structure of this alleved 'novel' benzodiazepine.
If the 2-methyl moiety has been swapped for the 2-ethyl, I suppose it will be active but less potant than the parent drug. My guess that this is the modification is based on the fact that if someone is making bromazolam, they only need to alter one simple precursor.
It also underlines the fact that the maker only has a shaky grasp of the QSAR of benzodiazepines. Mecolonazepam is the sole example of a benzodiazepine with a 3-methyl moiety. While most synthesis would produce the chiral product, the increased potency would more than offet the issue. That 3-methyl could be added to almost every RC benzodiazipine I know of. If someone is prepared to go chiral - the (R) enantiomer had an increadibly high affinity for certain GABA receptor subtypes (I read a table of affinity data decades ago).
If the 2-methyl moiety has been swapped for the 2-ethyl, I suppose it will be active but less potant than the parent drug. My guess that this is the modification is based on the fact that if someone is making bromazolam, they only need to alter one simple precursor.
It also underlines the fact that the maker only has a shaky grasp of the QSAR of benzodiazepines. Mecolonazepam is the sole example of a benzodiazepine with a 3-methyl moiety. While most synthesis would produce the chiral product, the increased potency would more than offet the issue. That 3-methyl could be added to almost every RC benzodiazipine I know of. If someone is prepared to go chiral - the (R) enantiomer had an increadibly high affinity for certain GABA receptor subtypes (I read a table of affinity data decades ago).
